Could Zika Virus Be Used to Treat the Brain Tumor GBM?

Advances in molecular genetics have led to the development of effective cancer treatments. One of these treatment methods is oncolytic virus vaccines. Research into oncolytic viruses has increased recently. Perhaps the most interesting study in this area was published in September 2017 in the Journal of Experimental Medicine . According to the study, Zika virus may be effective against the brain tumor glioblastoma (GBM) in treatment.
What Is Zika Virus?
Zika virus is a medically important RNA virus affecting the central nervous system and transmitted by mosquitoes. It is particularly dangerous for pregnant women. Pregnant women infected with Zika virus have a very high miscarriage risk. Their babies also develop neurological problems such as microcephaly (an abnormally small head).
Zika virus crosses the blood-brain barrier and targets neural stem cells in the developing brain, destroying them. Researchers tested whether this property of the virus could be used against brain tumors in laboratory cell and mouse models.
You May Be Interested In:
According to the Research Results;
- In the laboratory, Zika virus was observed to destroy human glioblastoma stem cells.
- Zika virus was also tested in mouse models of glioblastoma. Mice injected with Zika virus were observed to live longer.
- Researchers also tested the virus in brain cells taken from a healthy person. Zika virus did not infect these cells. This explains why Zika very rarely causes problems in adults.
So What Does This Study Mean Clinically?
- A new oncolytic virus against cancer has been identified. A product of genetic engineering technology and a type of cancer immunotherapy , oncolytic virus vaccines are among targeted cancer treatments. So far, only one oncolytic virus vaccine has been approved for clinical use: for malignant melanoma skin cancer, Lmlygic (talimogene laherparepvec). In addition, there is 1 other FDA-approved therapeutic cancer vaccine: the dendritic cell vaccine for prostate cancer, Provenge (Sipuleucel-T). As molecular genetic techniques advance, the number of oncolytic virus vaccines used clinically will increase.
- It must be emphasized that these study results are initial data from laboratory analyses. Efficacy in mouse cancer models does not mean the virus will have the same effect in humans. We also know that Zika virus affects humans and mice differently. Further studies will clarify its effects on human glioblastoma brain tumor cells.
- However, using Zika virus in its current form for cancer treatment is not safe. Although it is known not to cause serious health problems in adults, the virus can be transmitted by mosquitoes and sexual intercourse. Therefore, modern genetic techniques aim to modify Zika virus’s genetic structure to eliminate its disease-causing ability.
Sources
Zika virus has oncolytic activity against glioblastoma stem cells
Journal of Experimental Medicine Sep 2017
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.